What is Romark?
Founded in 1993 and headquartered in Tampa, Florida, Romark Laboratories is dedicated to pioneering novel small molecule therapeutics. The company's strategic focus spans both infectious diseases and oncology, areas with significant unmet medical needs. Romark's business model encompasses the full spectrum from initial discovery through to commercialization, positioning it as a comprehensive player in the biopharmaceutical landscape. The company's long-standing presence in the industry suggests a robust foundation in research and development, aiming to bring impactful treatments to patients.
How much funding has Romark raised?
Romark has raised a total of $73.2M across 7 funding rounds:
Private Equity
$23.1M
Private Equity
$9.6M
Private Equity
$15M
Private Equity
$10.8M
Debt
$10.7M
Debt
$2M
Debt
$2M
Private Equity (2009): $23.1M, investors not publicly disclosed
Private Equity (2010): $9.6M, investors not publicly disclosed
Private Equity (2013): $15M, investors not publicly disclosed
Private Equity (2014): $10.8M featuring Source Capital Group, Inc., Williams Financial Group, and International Assets Advisory, LLC
Debt (2015): $10.7M, investors not publicly disclosed
Debt (2020): $2M with participation from PPP
Debt (2021): $2M led by PPP
Key Investors in Romark
Source Capital Group, Inc.
Source Capital Group, Inc. is an investment banking firm specializing in small to medium-sized transactions, with a focus on independent and unbiased financial advice.
Williams Financial Group
Williams Financial Group is a financial services firm providing securities, brokerage, and advisory services to independent Financial Professionals.
International Assets Advisory, LLC
International Assets Advisory, LLC is an independent broker-dealer serving financial professionals and institutions since 1982.
What's next for Romark?
The recent major strategic investment signals a pivotal phase for Romark, likely aimed at accelerating clinical trials, expanding its research capabilities, or preparing for commercial launch of its lead candidates. Given the company's enterprise-level funding context, Romark is positioned for significant growth and market penetration. Future developments will likely focus on advancing its small molecule pipeline through key regulatory milestones and forging strategic partnerships to maximize the therapeutic potential of its discoveries in the competitive biopharmaceutical sector.
See full Romark company page
